Table 2.
Mean BP and proportion of participants reaching BP goal (<130/80 mm Hg) at weeks 12 and 52/ET
| Time point | Diabetes | CKD | Chronic CVD |
|---|---|---|---|
|
Week 12 | |||
|
n |
333 |
93 |
191 |
| OM 40/AML 5/HCTZ 12.5 mg* |
138.9/81.2 (17.4/9.6) |
135.0/76.5 (20.6/10.9) |
137.7/81.4 (15.7/10.3) |
| % to goal |
22 |
40 |
25 |
|
Week 52/ET | |||
|
n |
62 |
29 |
56 |
| OM 40/AML 5/HCTZ 12.5 mg |
121.4/74.9 (14.5/8.8) |
118.4/70.9 (12.6/7.9) |
127.1/77.1 (18.8/12.4) |
| % to goal |
65 |
79 |
54 |
| n |
34 |
13 |
29 |
| OM 40/AML 5/HCTZ 25 mg |
129.5/77.2 (15.6/9.9) |
126.5/72.4 (22.5/10.5) |
134.2/78.0 (17.0/11.6) |
| % to goal |
38 |
54 |
35 |
| n |
40 |
14 |
20 |
| OM 40/AML 10/HCTZ 12.5 mg |
128.8/77.0 (11.6/8.5) |
122.3/70.9 (15.6/8.1) |
132.9/77.6 (11.1/8.5) |
| % to goal |
50 |
43 |
20 |
| n |
197 |
36 |
86 |
| OM 40/AML 10/HCTZ 25 mg |
136.7/79.7 (15.2/9.7) |
134.0/75.0 (17.7/10.3) |
138.4/82.3 (16.2/10.6) |
| % to goal | 24 | 31 | 27 |
BP data are mean (SD), mm Hg.
*Week 12 data are from the end of the double-blind treatment period before all participants were switched to OM 40/AML 5/HCTZ 12.5 mg at the beginning of the open-label extension period.
AML, amlodipine; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; ET, early termination; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; SD, standard deviation.